2022
DOI: 10.3390/biomedicines10123122
|View full text |Cite
|
Sign up to set email alerts
|

Identification of the Transcriptional Regulatory Role of RUNX2 by Network Analysis in Lung Cancer Cells

Abstract: The use of a new bioinformatics pipeline allowed the identification of deregulated transcription factors (TFs) coexpressed in lung cancer that could become biomarkers of tumor establishment and progression. A gene regulatory network (GRN) of lung cancer was created with the normalized gene expression levels of differentially expressed genes (DEGs) from the microarray dataset GSE19804. Moreover, coregulatory and transcriptional regulatory network (TRN) analyses were performed for the main regulators identified … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 83 publications
0
2
0
Order By: Relevance
“…In our lung cancer bioinformatic analysis of TF RUNX2 [48], we analyzed and compared our pipeline and results [38,49] with previous studies, finding eleven publications assessing the lung cancer TRN with different microarray and RNA-seq studies; we also performed direct and very different bioinformatics analyses on datasets created or selected from the databases. Four studies were led with cell lines; five were made with one, two, or six microarray studies; and two were conducted with TCGA RNA-seq studies.…”
Section: Lung Cancermentioning
confidence: 99%
“…In our lung cancer bioinformatic analysis of TF RUNX2 [48], we analyzed and compared our pipeline and results [38,49] with previous studies, finding eleven publications assessing the lung cancer TRN with different microarray and RNA-seq studies; we also performed direct and very different bioinformatics analyses on datasets created or selected from the databases. Four studies were led with cell lines; five were made with one, two, or six microarray studies; and two were conducted with TCGA RNA-seq studies.…”
Section: Lung Cancermentioning
confidence: 99%
“…The deletion of the RUNT domain using the CRISPR/Cas9 technique lowered the cancer cell migration by a considerable margin [36], while its presence contributed to increased osteotropism and bone invasion in melanoma cells [37]. RUNX2 has also been shown to promote the aggressiveness of malignant gliomas [38] and act as a master transcriptional regulator in lung cancer [39] and in possibly all other cancers. RUNX2 is also a key epigenetic enhancer of tumor metastasis, stemness and resistance to therapy [40].…”
Section: Approachmentioning
confidence: 99%